Regular patient/clinician interaction can help increase follow-up cancer screening

August 17, 2012, University of Pennsylvania

The line “talk to your doctor,” which appears in so many medical-related advertisements, is apparently right. An analysis of colorectal cancer (CRC) patients who maintained regular contact with their clinicians (doctors, nurses, specialists) indicates those patients are more likely to follow recommendations for detecting cancer recurrence than patients who do not. In fact, researchers found CRC patients were more than twice as likely to adhere to medical follow up procedures if they had regular patient clinician information engagement (PCIE).

The study was conducted by a team of researchers from the Center of Excellence in Cancer Communication Research (CECCR) at the University of Pennsylvania’s Annenberg School for Communication. The research team—doctoral student Andy S.L. Tan; Mihaela Moldovan-Johnson, Ph.D.; doctoral student Sarah Parvanta; Stacy W. Gray, MD; Katrina Armstrong, MD; and Robert C. Hornik, Ph.D.—followed over 300 CRC since 2005. The results of their work currently appear in the journal The Oncologist, the official journal of the Society for Translational Oncology. The article title is “Patient-Clinician Information Engagement Improves Adherence to Colorectal Cancer Surveillance after Curative Treatment: Results from a Longitudinal Study.”

The patients in the study—roughly half male, half female; mostly white (88.5 percent); a mean age of 68; and most (72.5%) indicating concern about cancer recurrence—responded to surveys over the three-year span of the study. All reported whether they had received specific follow up screening tests—two or more office visits, two or more serum carcinoembryonic antigen (CEA) tests, and one colonoscopy. The study tracked how often these procedures were received in comparison to the amount of interaction patients had with their clinicians.

While only 41 percent reported receiving all three surveillance procedures, the researchers did note that patients who had consistent PCIE were 2.8 times more likely to adhere to recommended follow up tests.

In the article the research team acknowledges that several socio-demographic and clinical factors affecting whether or not someone follows advice cannot be modified. These include the patients’ age, income level, race, and severity (stage) of the cancer. However, they note that understanding the impact and effects of PCIE can help health professionals develop pilot interventions to improve adherence through patient active engagement with their clinicians on cancer-related information.

“We recommend that prospective studies be considered to determine if pilot programs encouraging active patient engagement with clinicians about -related information would be beneficial in terms of increasing the proportion of patients receiving post-treatment surveillance testing, and ultimately in improving patient outcomes and survival,” the researchers write in their conclusion.

Explore further: Patient navigators appear to improve colorectal cancer screening rate in ethnically diverse patients

More information: The Oncologist August 2012 doi: 10.1634/theoncologist.2012-0173

Related Stories

Patient navigators appear to improve colorectal cancer screening rate in ethnically diverse patients

May 23, 2011
Among low-income patients who are black or whose primary language is not English, patient navigators may help improve colorectal cancer (CRC) screening rates, according to a report in the May 23 issue of Archives of Internal ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.